Cargando…

Differences in mortality of cancer patients with COVID-19 in a Brazilian cancer center

INTRODUCTION: To analyze COVID-19 mortality in cancer patients and associated factors such as age, sex, type of insurance, situation at COVID-19 diagnosis, and cancer histology during the pandemic at a cancer center in Brazil. METHODS: Cross-sectional study carried out from April 02, 2020 to August...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandes, Gisele Aparecida, Feriani, Diego, França e Silva, Ivan Leonardo Avelino, Mendonça e Silva, Diego Rodrigues, Arantes, Paola Engelmann, Canteras, Juliana da Silva, da Silva, Rodrigo Reghini, Curado, Maria Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849494/
https://www.ncbi.nlm.nih.gov/pubmed/33573780
http://dx.doi.org/10.1053/j.seminoncol.2021.01.003
Descripción
Sumario:INTRODUCTION: To analyze COVID-19 mortality in cancer patients and associated factors such as age, sex, type of insurance, situation at COVID-19 diagnosis, and cancer histology during the pandemic at a cancer center in Brazil. METHODS: Cross-sectional study carried out from April 02, 2020 to August 31, 2020 at A.C. Camargo Cancer Center (ACCCC), in São Paulo, Brazil. Cases were extracted from the Hospital Cancer Registry. COVID-19 lethality rates by histology were calculated; multiple logistic regression was used to identify factors associated with COVID-19 mortality. The log-rank test was applied to compare the survival curves for each variable. RESULTS: Of the 411 patients analyzed, 51 (12.4%) died due to COVID-19. Death occurred at an average age of 63 years. The fatality rate was higher for lung (0.333) and hematological (0.213) cancers and was associated with age over 60 years. The greatest chances of death from COVID-19 were in cases of lung (odds ratio, OR, 4.05, 95% confidence interval, CI 1.33–12.34) and hematological (OR 2.17, 95% CI 0.96–4.90) cancers, and in patients currently undergoing cancer treatment (OR 2.77, 95% CI 1.25–6.13). There were no statistical differences in survival by sex, age group, type of insurance, situation at the diagnosis of COVID-19, and histology of cancer for COVID-19. CONCLUSIONS: Mortality due to COVID-19 in cancer patients is heterogeneous. These findings reinforce the need for individualized strategies for the management of different types of cancer that reduce the risk of death from COVID-19.